| Literature DB >> 32655307 |
Raiane C Chamon1, Lucas M Marques1, Jorge Timenetsky1, Caio T C da Costa Rachid1, Rosana B R Ferreira1, Tamara L R de Oliveira1, Thais Glatthardt1, Lilian de Oliveira Moreira1, Kátia R N Dos Santos1.
Abstract
BACKGROUND: Staphylococcus aureus isolates expressing the Panton-Valentine Leukocidin (PVL) have been related to a wide range of diseases. Recently, pvl-positive community-associated methicillin-resistant S. aureus belonging to USA1100 (ST30/CC30/SCCmec IV) lineage has emerged in Brazilian hospitals.Entities:
Keywords: MRSA; S. aureus; USA1100/ST30; VISA; pvl-positive; virulence
Year: 2020 PMID: 32655307 PMCID: PMC7324871 DOI: 10.2174/1389202921666200327105756
Source DB: PubMed Journal: Curr Genomics ISSN: 1389-2029 Impact factor: 2.236
Characterization of four phages incorporated into the genome of the MRSA 13420 isolate according to the PHASTER tool.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| #1 | Incomplete | 20 | 819741 | 838155 | 18.4 | 31.5 | 20 | NC_007045 |
| #2 | Complete | 100 | 1518148 | 1574122 | 55.9 | 33.1 | 78 | NC_012784 |
| #3 | Incomplete | 20 | 1901925 | 1918694 | 16.7 | 28.9 | 19 | NC_031125 |
| #4 | Complete | 100 | 2043339 | 2078729 | 35.3 | 33 | 48 | NC_008617 |
*Percentage of identity with the reference genome; †Genome Accessing Number; Kb Kilobases; CDS Coding DNA Sequence.
Comparison of amino acid substitutions at genes associated with vancomycin intermediate resistance among Staphylococcus aureus 13420 and hVISA, VISA and VSSA isolates previously sequenced.
|
|
|
|
|
|
|---|---|---|---|---|
|
|
| I5Nb,c, G88D, L123H, S167N, | nd | [ |
|
| nd | E59D, A113V, S164P | S26R, E59D, F85L, I86L, E87K, A113V, R117H, R121S, S164P | [ |
|
| nd | R14L, L26F, M29R, I59L, D148Q, A153P, T224I, N289Y, V301E, V304E, N332K | L26F, I59L, D148Q, T224I, S303R, R325K, N332K, V676I | [ |
|
| nd | D148Q, F151L, N197Sb | M90N, D147E, D148Q, S197G, V135I, V136I | [ |
|
| F31L, | M202T, | K2E, N133I, M202T, | [ |
|
| L173M, | A91P, I232L, W308G | H6Y, V145F, F207L, S341N, | [ |
a MIC of 4 mg/L for vancomycin; hVISA – S. aureus with heterogeneous intermediate resistance to vancomycin; VISA – S. aureus with intermediate resistance to vancomycin; VSSA – Vancomycin susceptible S. aureus; bMu50 - VISA clinical strain with vraS (I5N), msrR (E146K),graR (N197S),rpoB (H481Y), and fdh2 (A297V) mutations and MIC of 12 mg/L for vancomycin; c Mu3- hVISA clinical strain with vraS (I5N) and msrR (E146K) mutation and MIC of 3 mg/L for vancomycin; d H14 - hVISA strain with vraS (S329L) mutation and MIC of 2 mg/L for vancomycin; A Alanine; D Aspartic acid; E Glutamic acid; F Phenylalanine; G Glycine; H Histidine; I Isoleucine; K Lysine; L Leucine; M Methionine; N Asparagine; P Proline; Q Glutamine; R Arginine; S Serine; T Threonine; V Valine; Y Tyrosine; nd - not detected; n - number of isolates; In bold: mutations found among 13420 and hVISA/VISA and VSSA isolates.
Molecular, clinical characteristics and relative pvl expression of six pvl-positive S. aureus isolates.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 526 | USA300/ST8 | IV | renal abscess secretion | 1 | 0.07 |
| 559 | USA800/ST5 | IV | peritoneal liquid | 0.903 | 0.04 |
| 945 | USA400/ST1 | IV | nares | 0.002 | 0.01 |
| 1155 | USA1100/ST30 | IV | bone secretion | 4.597 | 0.10 |
| 13420† | USA1100/ST30 | IV | blood | 5.378 | 0.01 |
| 1348 | USA400/ST1 | na | blood | 1.146 | 0.03 |
*relative pvl expression in comparison with 526 (USA300/ST8) isolate; †isolate sequenced at the present study; ST - Sequence type; SCCmec - Staphylococcal Cassete Chromosome mec; SD - standard deviation; na - not applicable (methicillin-sensitive isolate). The experiments were performed in three independent triplicates.